EOCI has a demonstrated track record of over 18 years in the CME industry. Our reputation is a result of business integrity and professional agility, as well as resourcefulness and creativity.
In addition to the 50-100 CME programs we develop annually, EOCI produces other high-calibre specialist-focused annual congresses across Canada.
Dr. Shelley Zieroth joined the Section of Cardiology at St. Boniface Hospital in Winnipeg in July 2006. She is currently an Associate Professor in the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics. She is also Head of the Medical Heart Failure Program for the Winnipeg Regional Health Authority, Cardiac Sciences Program.
Dr. Zieroth attended medical school at the University of Manitoba and went on to train in Internal Medicine and Cardiology at the same centre. She completed her Postdoctoral Clinical Fellowship, specializing in Advanced Heart Failure and Cardiac Transplant, at Toronto General Hospital.
She is involved in several heart failure clinical trials. Her area of research examines the efficacy of new treatments including food derived bioactives, in human heart failure. She is the current President of the Canadian Heart Failure Society and on the Canadian Cardiovascular Society Primary Panel for Heart Failure Guidelines. Her current passion is working with national and provincial Patient Advocacy groups and Primary Care to operationalize hub and spoke models of heart failure care. In 2017 she was appointed to the Heart and Stroke Foundation Mission Critical Area Council on Heart Failure.
Jeff Healey is a Cardiologist/Electrophysiologist and Professor of Medicine at McMaster University
He is the director of the division of cardiology, and the Population Health Research Institute Chair in Cardiology. He is the chair of the Canadian Stroke Prevention and Intervention Network (CSPIN) and past chair of the Canadian atrial fibrillation guidelines committee.
He was the lead author of the ASSERT trial, which was published in the New England Journal of Medicine in 2012 and demonstrated the increased stroke risk associated with sub-clinical atrial fibrillation detected by pacemakers. He was also the lead author of the RELY AF cohort study, a 15,000-patient worldwide registry, published in the Lancet in 2016, examining the causes, treatment and outcomes in patients with atrial fibrillation.
He currently leads the ARTESIA trial, evaluating the role of anticoagulation in patients with subclinical AF.
Dr. Grace Chua is a staff cardiologist at Mackenzie Health in Richmond Hill/Vaughan, Ontario. She obtained her medical degree from the University of Toronto, followed by internal medicine and cardiology training at University Health Network in Toronto, including a fellowship in Clinical Epidemiology and Adult Echocardiography. During her cardiology training, she did research combining clinical epidemiology and cardiology leading to a publication in the New England Journal of Medicine that has been instrumental in initiating the declaration of conflict of interest in medicine that we see today. She is a Fellow of the Royal College of Physicians and Surgeons in Cardiology as well as a Fellow of the American College of Cardiology. As a community cardiologist, she was the Chief of the Division of Cardiology at Mackenzie Health from September 2003 to March 2017 and was the initiating force in the development of the hospital’s rapid access chest pain clinic and heart function service. Currently, her interests lie in clinical education and knowledge translation, particularly in the field of heart failure, as well as prevention of cardiovascular disease.
Dr. Atul Verma is a staff cardiac electrophysiologist and Director of Arrhythmia Services at Southlake Regional Health Care Centre in Newmarket, Ontario, Canada. He is affiliated with the University of Toronto and McGill University. Specific interests include ablation of atrial fibrillation and ventricular tachycardia.
Dr. Verma is co-chair of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee and serves other international guideline committees.
Dr. Verma completed his medical school and cardiology residency at the University of Toronto and then specialized in cardiac electrophysiology at the Cleveland Clinic. He has published over 150 peer-reviewed articles in the New England Journal of Medicine, Circulation, JACC, JAMA, JAMA Internal Medicine, European Heart Journal, and others.
Dr. Dehghan is an Investigator for the Nutrition Epidemiology program at the Population Health Research Institute. She holds two Masters of Clinical Nutrition and Health Research Methodology, and received her doctoral degree in Clinical Nutrition from Newcastle University, England. Dr. Dehghan completed post-doctoral training in Nutrition Epidemiology at McMaster University. During the last seventeen years, her main focus has been the development of methods to measure dietary intake of individuals around the world. Dr. Dehghan is the nutrition lead of the Population Urban and Rural Epidemiological (PURE) study and the INTERSTROKE study. Her main interest is understanding the impact of dietary factors in the cause and prevention of cardiovascular disease and cancer. She has published 57 papers and 2 book chapters.
Dr Katie Connolly is a Cardiologist with training in Advanced Heart Failure and Cardiac Transplantation, and also in Advanced Echocardiography. She is an Assistant Professor of Medicine at McMaster University and is the clinical lead of the Cardiac Amyloidosis clinic at Hamilton General hospital.
Dr. Anique Ducharme is a Professor of Medicine at Université de Montréal and holds the University of Montreal Fondation Marcelle and Jean Coutu, Cal & Janine Moisan for better practices in advanced heart failure. She is also the founder and Director of the Heart Failure Clinic at the Montreal Heart Institute (MHI) and a former Senior Clinical Researcher at the Fonds québécois de recherche en santé (FQRS). She is vice- president of the Canadian Heart Failure Society (CHFS) and the chair of the Scientific Program Committee for the Canadian Cardiovascular Congress. In addition, she is an active member of the CCS Heart Failure Guidelines Committee, sitting on the primary panel since 2006.
Dr. Ducharme graduated from Université de Montréal in 1991 in Medicine (MD) and Biomedical sciences (MSc, cardiac transplantation) and completed her residency in Cardiology in 1996. She pursued additional training in Echocardiography at the Montreal Heart Institute, then in Molecular Biology and Heart Failure at the Brigham & Women’s Hospital, Harvard Medical School in Boston. Since her return in 1999, she has held a position in the Noninvasive Cardiology department at the Montreal Heart Institute, where she carries out activities in echocardiography, advanced heart failure and cardiac transplantation. Her clinical and research focus is on advanced heart failure, including remodeling, pharmacological and device therapies (cardiac resynchronization therapy, mechanical assist devices and transplantation).
Dr. Ducharme has published over 150 peer-reviewed articles, 15 book chapters, 200 abstracts and 2 online university tutorial courses (Echocardiography Certificate, University of Melbourne, Australia).
She is currently PI for the SELFIE (Virtual HF clinic) and the CHAMP trials, and has sat on the executive committee of the CANSAVER and EARTH studies. Dr. Ducharme has served on several steering committees for large-scale studies, including GUIDE-HF, STICH, AF-CHF, EARTH, RELAX-HF and CHARM. She also participates in several review panels for journals, including Circulation, the Journal of the American College of Cardiology, the Journal of Cardiac Failure, the Canadian Medical Association Journal and the Canadian Journal of Cardiology.
Dr. Hertzel C. Gerstein is a Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Research Institute Chair in Diabetes and is the Director of the Diabetes Care and Research Program and Deputy Director of the Population Health Research Institute.
Dr. Gerstein’s research has been published in over 400 papers, spans 50 countries, and has been funded by the NIH, the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, the Canadian Diabetes Association and the pharmaceutical industry. His research focuses on: a) the prevention and therapy of diabetes and its many consequences; b) the relationship between dysglycemia (a term he coined in 1995), cardiovascular outcomes, cognitive impairment, other diabetes-related chronic consequences, and new diabetes; c) strategies for type 2 diabetes remission; d) novel biomarkers for cardiovascular disease in diabetes; and e) the biologic basis of glucose-related health consequences. In 2016 he produced and distributed a music video to mitigate the impact of diabetes on affected people and their families. In 2012 he received the Canadian Diabetes Association’s Lifetime Achievement Award.
Dr. Jean C. Grégoire received his MD from the University of Montréal in 1985. He performed his residency in Internal Medicine and Cardiology in 1990 at the same University. He completed training in interventional cardiology at the Quebec Heart Institute, followed by two years of animal model study of coronary restenosis after angioplasty and endothelial dysfunction at the Mayo Clinic, Rochester, Minnesota.
He is an Associate Clinical Professor at the University of Montreal and works in the Interventional Cardiology Service, Coronary Care Unit, and in clinical research at the Montréal Heart Institute. He is the author of several book chapters and scientific publications. He is a former co-chair of the Canadian Dyslipidemia Guideline (2012 and 2016) and current member of the primary committee of the Lipid and Hypertension Canada guidelines. His principal research interests include the role of oxidative stress and inflammation in atherosclerosis and endothelial dysfunction, atherosclerotic plaque imaging, dyslipidemia, diabetes, hypertension and acute coronary syndrome.
Dr. Peter Liu is Scientific Director of the University of Ottawa Heart Institute, as well as Professor of Medicine and Physiology at the University of Toronto and the University of Ottawa. He currently serves as President of the International Society of Cardiomyopathy and Heart Failure of the World Heart Federation, and is a former Scientific Director of the Institute of Circulatory and Respiratory Health at the Canadian Institutes of Health Research. He received his MD from the University of Toronto, and did his postgraduate training at Harvard University. His laboratory investigates the causes and treatments of heart failure, the role of inflammation and the identification of novel biomarkers and interventions in cardiovascular disease. He has published over 300 peer-reviewed articles in high-impact journals, and has received numerous awards in recognition of his research and scientific accomplishments. He has chaired or co-chaired scientific sessions of the Heart Failure Society of America, the International Society of Heart Research and the Human Proteomic Organization, among others. He reviews programs for major international funding agencies including European Frameworks, Wellcome Trust, US National Institutes of Health and NASA. He is also a champion of knowledge translation, integrating the Cardiovascular Prevention Guidelines and the Healthy Heart Policy in Canada and internationally. The harmonized Canadian C-CHANGE Guidelines were recently chosen by all the provincial premiers in Canada as the first cardiovascular guidelines to be mandated by Ministries of Health across the country.
Dr Nault has obtain his medical diploma from the University of Montreal where he has also be trained in general surgery. He completed his fellowship in vascular surgery at McGill University and he is a member of the Royal College of Surgeons of Canada. Since 1995, he is the chief of vascular and endovascular surgery in the Gatineau campus of McGill University, where he is an associate professor. In 2009, he received the “Excellence Award” in teaching. You can see his last teaching video on ABI on the web-site of the Quebec Society for Vascular Science, the SSVQ, Society still very active co-funded with colleagues in 2000.
Dr. Nault is the medical director of the research unit and his team has participated in more than 50 international clinical trials. His research interest include peripheral arterial disease (PAD) and open repair of Abdominal Aortic Aneurysm (AAA). He is the second author of the sub-study of the PAD patients in the FOURIER trial, he was the top enroller in Canada in VOYAGER trial and he presented in 2018 at the Society of Vascular Surgery annual meeting in Boston , his personal series of 316 consecutives cases of Open repair of AAA over a decade with a 30-day mortality rate of 0.3%.
Dr. Nault is the medical director of the first North American French speaking ICAVL accredited vascular laboratory, the first Quebec vascular surgeon to participate in the North American Vascular Quality Initiative (VQI) and an accomplish marathoner who do encourage all his PAD patients to participate in exercise training and walk/run public events. He ran the Boston Marathon last year.
Dr. Shamir Mehta is a Professor of Medicine at McMaster University, Director of the Interventional Cardiology program at Hamilton Health Sciences and Senior Scientist at the Population Health Research Institute in Hamilton, Canada. He graduated from the University of Toronto’s Faculty of Medicine where he also completed internal medicine and cardiology training, followed by an interventional cardiology fellowship at the University Health Network. He completed a research fellowship and Master’s in Health Research Methodology at McMaster University and received a CIHR New Investigator Award. He was named one of Canada’s Top 40 Under 40.
He has a busy interventional cardiology practice and leads the percutaneous mitral valve program at HHS. He co-chairs the Canadian Cardiovascular Society Antiplatelet Therapy Guidelines. His research focuses on the role of percutaneous invasive therapies in patients with acute ischemic heart disease, and the evaluation of novel antithrombotic therapies and structural heart interventions.
Dr. Mehta has published over 200 articles and holds operating grants from the CIHR, Heart and Stroke Foundation and industry. He has led practice-changing trials in patients with acute coronary syndromes, having been the Principal Investigator of the PCI-CURE study establishing the benefit of clopidogrel in patients with ACS undergoing PCI and the 25,000 patient CURRENT-OASIS 7 trial evaluating aspirin and clopidogrel dosing. He is the Principal Investigator of PREMISE, a Canadian multicenter registry of patients undergoing percutaneous mitral valve repair with the Mitraclip. He has also led landmark trials evaluating pragmatic interventions in ACS, including RIVAL, establishing the benefit of a radial artery versus femoral artery approach in patients with ACS, TIMACS evaluating optimal timing of invasive intervention in patients with ACS and the recently published COMPELTE trial evaluating a strategy of complete revascularization in patients with STEMI and multivessel disease. The COMPLETE trial was recognized by the editors of the New England Journal of Medicine as one of its Most Notable Articles of 2019 and by the board of the American Heart Association as a top 10 research advance of 2019.
Dr. Léna Rivard obtained her medical degree from the University of Lariboisière, Paris and has two Master’s degrees (Clinical Research Methods and Biostatistics).
She completed a 3-year-fellowship in research and clinical electrophysiology at the Montreal Heart Institute and at the Université de Bordeaux with Professor Michel Haïssaguerre.
In 2010, Dr. Rivard was recruited as a staff electrophysiologist and clinician investigator at the Montreal Heart Institute. Her speciality is in the domain of complex catheter ablation procedures.
She is a member of the Canadian Cardiovascular Ventricular tachycardia Guidelines Committee.
She is the principal investigator of two ongoing multicenter studies: the BRAIN-AF trial funded by the Canadian Stroke Prevention Network (C-SPIN), the Montreal Heart Institute Foundation and BAYER global and the COME-TAVI trial funded by the Heart and Stroke Foundation of Canada. Dr. Rivard also received research salary support from the FRSQ (Fonds recherche en sante du Quebec).
Dr Kiran Sidhu joined the Section of Cardiology at St. Boniface Hospital in September 2019. She is currently an Assistant Professor in the Max Rady College of Medicine at the University of Manitoba. Dr Sidhu obtained her BSc. Pharm as well as her M.D. at the University of British Columbia. She completed her internal medicine residency in Vancouver, cardiology residency at the London Health Sciences Centre (LHSC), followed by a fellowship in Cardiac Rhythm Devices there. Most recently, she completed her Advanced Heart Failure and Cardiac Transplantation fellowship at the Brigham and Women’s Hospital in Boston. As well, she is in the midst of completing a Master of Public Health through the Harvard T.H Chan School of Public Health. She is a member of the National Heart Transplant Advisory Committee.
Dr. Siegal graduated from Queen’s University School of Medicine in 2009. She completed Internal Medicine and Hematology training at McMaster University. She holds Master of Science degrees in Pharmacology (University of Toronto) and Health Research Methodology (McMaster University).
Dr. Siegal is currently Assistant Professor in the Division of Hematology and Thromboembolism, Scientist at the Population Health Research Institute and Investigator at the Thrombosis and Atherosclerosis Institute at McMaster University. Her primary research interest is improving the safety of anticoagulant therapy including optimizing the management of anticoagulant-related bleeding complications and restarting anticoagulants after bleeding. She has published over 60 articles in peer-reviewed journals including The New England Journal of Medicine, Circulation, Blood and Journal of Thrombosis and Haemostasis on the topic of anticoagulant-associated bleeding and reversal.
Jean-Claude Tardif is the Director of the Research Centre at the Montreal Heart Institute and Professor of Medicine at the University of Montreal. Dr Tardif graduated from the University of Montreal with his medical degree in 1987 and completed his training in cardiology and research in Montreal and Boston in 1994. Dr Tardif holds the Canada Research Chair in personalized medicine and the University of Montreal endowed research chair in atherosclerosis. He is the Scientific Director of the Montreal Health Innovations Coordinating Centre (MHICC) and Chairman of the steering committees of the CIHR-funded Canadian Atherosclerosis Imaging Network (CAIN) and Medical Imaging Trials NEtwork of Canada (MITNEC).
His research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves animal models, mechanistic and observational clinical studies as well as early clinical studies and large international randomized clinical trials. Dr Tardif is or has been the international principal investigator or part of the study leadership of several large clinical trials in the field of atherosclerosis and other cardiovascular diseases. Dr Tardif and his team have created the Beaulieu-Saucier Pharmacogenomics Center at the Montreal Heart Institute and he has created the Center of Excellence in Personalized Medicine, the latter funded by the Network of Centers of Excellence of Canada and which is also supported by multiple pharmaceutical and biotechnological companies.
Dr Tardif has authored more than 600 scientific articles and has won multiple awards during his career, including the Research Achievement Award of the Canadian Cardiovascular Society, the Distinguished Lecturer Award of the Canadian Institutes for Health Research, the Genesis Award of BIOQuébec (for his outstanding contributions to life sciences) and the Armand-Frappier Award of the Government of Québec (the highest scientific honour). He was also named scientific personality of the year by La Presse newspaper. Because of his accomplishments, Dr Tardif was named Fellow of the Canadian Academy of Health Sciences (FCAHS) and was recently inducted in the Order of Canada (the highest distinction in the country).
Dr. Jay Udell is a Cardiologist and Clinician-Scientist at Women’s College Hospital and the Peter Munk Cardiac Centre of the University Health Network; and an Associate Professor of Medicine at the University of Toronto.
He has a research focus on the cardiovascular benefits and risks of diabetes therapies and novel risk factor interventions, such as influenza vaccination. His team’s work is leading to alterations in national and international practice guidelines and impacting clinical practice.
Salim Yusuf, D.Phil, FRCPC is a Distinguished University Professor of Medicine at McMaster University, and Executive Director of the Population Health Research Institute in Hamilton, Canada. He has been inducted into the Royal Society of Canada and the Canadian Medical Hall of Fame, and has been appointed as an Officer of the Order of Canada, as well as winning the Canada Gairdner Wightman award. He has led over 50 major international collaborative studies that have enhanced strategies to prevent cardiovascular disease globally. He is a Past President of the World Heart Federation, where he initiated an Emerging Leaders program in 100 countries with the aim of halving the CVD burden globally within a generation.